Mirati Therapeutics - MRTX Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRTX, but not buy additional shares or sell existing shares.
View MRTX analyst ratings or view top-rated stocks.

13 brokerages have issued 12-month price targets for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $50.00 to $188.00. On average, they anticipate the company's share price to reach $80.87 in the next twelve months. This suggests a possible upside of 106.8% from the stock's current price.
View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts.

Mirati Therapeutics' stock was trading at $45.31 at the start of the year. Since then, MRTX stock has decreased by 13.7% and is now trading at $39.10.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our MRTX earnings forecast.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its quarterly earnings results on Tuesday, February, 28th. The biotechnology company reported ($3.51) EPS for the quarter, beating the consensus estimate of ($3.74) by $0.23. The biotechnology company earned $0.93 million during the quarter, compared to the consensus estimate of $2.65 million. Mirati Therapeutics had a negative net margin of 5,957.44% and a negative trailing twelve-month return on equity of 66.05%. Mirati Therapeutics's revenue was up 212.4% on a year-over-year basis. During the same period in the prior year, the business earned ($3.72) EPS.

ETFs with the largest weight of Mirati Therapeutics (NASDAQ:MRTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and WisdomTree BioRevolution Fund (WDNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.65%), Armistice Capital LLC (6.06%), Morgan Stanley (2.93%), Price T Rowe Associates Inc. MD (2.46%), Point72 Asset Management L.P. (1.31%) and Franklin Resources Inc. (1.28%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Henry J Fuchs, Isan Chen, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends.

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRTX stock can currently be purchased for approximately $39.10.

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.27 billion and generates $12.44 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($13.18) on an earnings per share basis.

The company employs 413 workers across the globe.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.